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Focal defects in the articular cartilage occur due to sporting 
activities, trauma, or other activities of daily living. Given 
that these defects can impair quality of life1 and predispose 
the adjacent cartilage to progressive degeneration,2,3 these 
localized lesions are often surgically treated in young and/
or active patient populations.4,5 In addition to currently 
available treatment options, including autologous cartilage 
implantation and osteochondral allografting,4,6-10 tissue 
engineering (TE) and regenerative medicine approaches 
have been pursued, combining various cell sources, scaf-
folding materials, and biochemical and biomechanical fac-
tors, to engineer cartilage formation either in vitro or in 
vivo.
Over the past 2 decades, steady advances in in vitro cul-
ture methods have culminated in a variety of TE approaches 
that can produce engineered constructs with biomechanical 
and biochemical properties on the order of native carti-
lage.11-20 As an example, our group has utilized an approach 
involving the combination of mesenchymal stem cells 
(MSCs) embedded within hyaluronic acid (HA) hydrogels. 
When exposed to chondrogenic factors, including trans-
forming growth factor–β3 (TGF-β3), these constructs 
achieve near native biomechanical and biochemical proper-
ties during in vitro culture.12,20 However, it remains an open 
question as to whether these components must first be cul-
tured in vitro to form tissue engineered cartilage or if they 
can be combined immediately prior to implantation to suc-
cessfully induce cartilage repair in vivo.
Given that preculture would dramatically increase costs 
associated with therapeutic intervention, this study focused 
on the latter scenario, using our established porcine model of 
cartilage injury and repair.21,22 Although many large animal 
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Abstract
Objective. We have recently shown that mesenchymal stem cells (MSCs) embedded in a hyaluronic acid (HA) hydrogel 
and exposed to chondrogenic factors (transforming growth factor–β3 [TGF-β3]) produce a cartilage-like tissue in vitro. 
The current objective was to determine if these same factors could be combined immediately prior to implantation to 
induce a superior healing response in vivo relative to the hydrogel alone. Design. Trochlear chondral defects were created 
in Yucatan mini-pigs (6 months old). Treatment groups included an HA hydrogel alone and hydrogels containing allogeneic 
MSCs, TGF-β3, or both. Six weeks after surgery, micro-computed tomography was used to quantitatively assess defect 
fill and subchondral bone remodeling. The quality of cartilage repair was assessed using the ICRS-II histological scoring 
system and immunohistochemistry for type II collagen. Results. Treatment with TGF-β3 led to a marked increase in positive 
staining for collagen type II within defects (P < 0.05), while delivery of MSCs did not (P > 0.05). Neither condition had an 
impact on other histological semiquantitative scores (P > 0.05), and inclusion of MSCs led to significantly less defect fill (P 
< 0.05). For all measurements, no synergistic interaction was found between TGF-β3 and MSC treatment when they were 
delivered together (P > 0.05). Conclusions. At this early healing time point, treatment with TGF-β3 promoted the formation 
of collagen type II within the defect, while allogeneic MSCs had little benefit. Combination of TGF-β3 and MSCs at the 
time of surgery did not produce a synergistic effect. An in vitro precultured construct made of these components may be 
required to enhance in vivo repair in this model system.
Keywords
cartilage, repair, mesenchymal stem cells, TGF-β3, animal models
Fisher et al. 175
studies have applied exogenous TGF and MSCs in vivo for 
cartilage repair,22-44 few studies have used a full factorial 
design to determine the relative impact of one component 
versus another or to identify synergistic effects. Even in the 
small number of studies with full factorial designs, the 
results are unclear, with some studies reporting improved 
histological appearance when MSCs were combined with 
TGF-β,40 and others showing little improvement relative to 
TGF-β alone.39 Numerous variables likely contribute to 
these contrary results, including animal species, injury 
model, scaffolding material, growth factor type, dosage, 
and delivery method, cell type and number, and so on.
These differences suggest that generalized statements 
about the effects of a growth factor or cell type may not be 
possible and that it is necessary to explore the components 
of each TE system for each specific animal and injury 
model. As such, the objective of the current study was to 
determine whether growth factor or cell delivery (i.e., TGF-
β3 or MSCs) within an HA hydrogel could induce a supe-
rior healing response in vivo when each factor was delivered 
alone or in combination in a porcine model of full thickness 
cartilage repair. We hypothesized that the combined treat-
ment of MSCs and TGF-β3 within the HA hydrogels would 
result in the most robust positive healing response.
Methods
All animal procedures were performed at the Philadelphia 
VA Medical Center with approval from the Institutional 
Animal Care and Use Committee and in accordance with 
policies set forth by the National Institutes of Health. Eight 
adolescent, male Yucatan mini-pigs (6 months old, ~25-35 
kg) were utilized (Sinclair Bioresources). Experimental 
groups included (Fig. 1B): (1) treatment with an acellular 
HA hydrogel (HA), (2) treatment with an HA hydrogel 
seeded with MSCs (HA/MSCs), (3) treatment with an HA 
hydrogel containing alginate microspheres encapsulating 
TGF-β3 (HA/TGF),45 and (4) treatment with an HA hydro-
gel seeded with MSCs and containing microspheres encap-
sulating TGF-β3 (HA/MSCs/TGF). Normal cartilage served 
as a control for all groups. To examine the early term effects 
of the various treatments, 1 animal with defects treated with 
HA, HA/MSCs, HA/TGF, and HA/MSCs/TGF (n = 1 per 
group) was euthanized at 2 weeks postoperatively. The 
remaining 7 animals were evaluated at 6 weeks postopera-
tively. Not all treatment groups were performed in the same 
set of animals, and other groups not reported here were also 
evaluated, giving rise to the unequal sample sizes (HA, n = 
7; HA/MSCs, n = 4; HA/TGF, n = 7; HA/MSCs/TGF, n = 
8). To minimize the number of animals used, an untreated 
control was not included in the study design, as this was 
described in our previous publication using this identical 
model.21 In that study, delivery of HA gel alone caused no 
statistically significant changes in the outcome measures 
described.
To form the HA hydrogel, methacrylated HA was syn-
thesized by reacting methacrylic anhydride (Sigma) and 74 
kDa HA (Lifecore) as previously described.17,18,20 Two days 
before surgery, the HA macromer was sterilized by expo-
sure to an ultraviolet lamp for 15 minutes. Afterward, a 
solution of 1.5% HA (mass/volume) with 0.05% 
Irgacure-2959 photoinitiator (Ciba-Geigy) was produced in 
phosphate buffered saline.
Alginate microspheres containing TGF-β3 were pre-
pared as previously described using an emulsion/gelation 
technique.45 Alginic acid sodium salt (Sigma) was dissolved 
in deionized water (2.3% w/v) with bovine serum albumin 
(1% w/v) combined with TGF-β3 (R&D Systems) in solu-
tion to achieve a final alginate concentration of 2% (w/v) 
and a TGF-β3 concentration of 12.5 μg/mL. The alginate/
TGF-β3 mixture was added dropwise to an excess of olive 
oil under stirring conditions. Tween 80 (1% (v/v)) was used 
as a surfactant. The emulsion was allowed to mix for 3 min-
utes. Afterward, a calcium chloride solution (200 mM) was 
added dropwise, and the alginate was allowed to crosslink 
for 15 minutes. The solution was then centrifuged at 1500g 
for 5 minutes to isolate the microspheres. After removal of 
the supernatant, particles were resuspended in 2-propanol to 
remove the residue oil and centrifuged again. This washing 
process was repeated a total of 3 times, followed by 4 washes 
with sterile deionized water to remove the 2-propanol. To 
enable controlled release of the TGF-β3, microspheres were 
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coated with nanofilm layers of poly(allylamine hydrochlo-
ride) (molecular weight [MW] 15 kDa) and poly(sodium 
4-styrenesulfonate) (MW 1 MDa) (Sigma), as previously 
described.45,46 This approach results in a roughly linear 
release of TGF-β3 for up to 5 to 7 days in vitro. For in vivo 
implantation, microspheres were mixed with HA solution to 
obtain a final concentration of 2 μg/mL of TGF-β3 and 1% 
(w/v) of HA solution.
MSCs were obtained from 2 mini-pigs (6-month-old 
males) in a parallel study immediately after euthanasia. A 
Jamshidi needle was used to obtain a bone marrow aspirate 
from the iliac crest. Marrow was diluted in Dulbecco’s 
modified Eagle’s medium (DMEM) containing heparin. 
Following centrifugation, marrow was plated onto tissue 
culture plates in basal medium (DMEM with 10% fetal 
bovine serum and 1% penicillin/streptomycin/fungizone as 
previously described.47 MSC colonies formed within 2 
weeks. Cells were frozen in liquid nitrogen until further use. 
Before surgery, cells were plated at 20,000 cells/cm2 and 
expanded to passage 2 in basal media. Cells from the 2 
donors were then pooled. For the 2-week time point, MSCs 
were tagged with a fluorescent dye (Vybrant DiD, Molecular 
Probes) to enable tracking in vivo. Immediately prior to 
implantation, cells were resuspended in HA solution to 
achieve a concentration of 60 million cells/mL and 1% HA.
For surgery, animals were sedated with ketamine and 
xylazine, and anesthesia was maintained throughout with 
isoflurane. A lateral parapatellar arthrotomy through a 
medial-based knee incision was made to the stifle joint, and 
the patella was retracted medially to expose the trochlear 
groove of the femur. Full-thickness chondral defects (4 mm 
diameter) were created bilaterally in the trochlear groove (4 
defects per joint) using a biopsy punch as previously 
described (Fig. 1A).21 The cartilage was completely removed 
(~2 mm thickness) without macroscopic removal of the sub-
chondral bone. No microfracture was performed. For all 
groups, HA hydrogels were polymerized in situ via exposure 
to ultraviolet light (365 nm, 1 mW/cm2, Omnicure S2000, 
Lumen Dynamics Group) for 10 minutes. Defect volume 
was ~0.025 mL, allowing for delivery of 50 ng of TGF-β3 
and 1.5 million MSCs per defect. Previous studies have indi-
cated that no other means of fixation are required to keep the 
hydrogels within the defects.21,22
After defect creation and repair, layered closure was per-
formed using absorbable sutures. Animals were provided 
bupivacaine and carprofen for postoperative pain control. 
Animals were allowed free movement and weight bearing 
as tolerated, with no specific rehabilitation protocols pre-
scribed. At 2 or 6 weeks postoperatively, animals were euth-
anized with an overdose of pentobarbital. Afterward, hind 
limbs were disarticulated at the hip and the trochlear groove 
of each joint was carefully exposed. After gross inspection 
and imaging, individual cartilage defects with underlying 
bone as well as normal osteochondral samples were isolated 
and fixed in 4% paraformaldehyde.
For the samples at 2 weeks, cell nuclei in whole mount 
samples were stained with Hoechst stain. Using an Olympus 
Fluoview FV1000 confocal microscope (Olympus America 
Inc., Center Valley, PA), confocal stacks were acquired 
from the edge of the defect to a depth of 100 μm from the 
cartilage surface. Samples were then dehydrated, paraffin 
embedded, sectioned to 6 μm, and stained to assess cell 
morphology (hematoxylin and eosin).
For the 6-week time point, micro-computed tomography 
(μCT) was performed to assess the 3D morphometry of the 
healing cartilage and bone (Viva CT75, Scanco).48-50 
Specimens were first μCT scanned to image the bone (70 
kVp, 110 μA). Samples were then placed in an iodine-based 
contrast solution (Lugol’s solution, Sigma) for 48 hours and 
rescanned using the same parameters to visualize the carti-
lage. Bone volume per total volume (BV/TV) was calcu-
lated for the first 2 mm and for a region 3 to 5 mm beneath 
the original defect for each specimen.21 Degree of defect fill 
was determined as a percentage of the total defect volume 
from the contrast-enhanced micro-computed tomography 
(μCT) images.
Following μCT, samples were decalcified (Formical 
2000, Decal Chemical Corporation) for 1 week and pre-
pared for histology as above to assess cell morphology 
(hematoxylin & eosin) and matrix content (proteoglycan 
and collagen/fibrous matrix via Safranin O and fast green, 
respectively). Slides were scored using a modified ICRS-II 
system51 by 5 blinded reviewers, with scores averaged 
across reviewers.
Figure 1. (A) Illustration of cartilage defects created in 
the trochlear groove and schematic of polymerization of the 
hyaluronic acid (HA) hydrogel within the defect via ultraviolet 
(UV) light. (B) Schematic of experimental groups. HA = 
hyaluronic acid; MSCs = mesenchymal stem cells; TGF = 
microspheres containing transforming growth factor-β3.
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To assess the deposition of type II collagen via immuno-
histochemistry, sections were deparaffinized, rehydrated, and 
subjected to proteinase K antigen retrieval. Sections were 
incubated with a type II collagen antibody (5 μg/mL; 
Developmental Studies Hybridoma Bank, University of 
Iowa) for 1 hour. After washing, the antibody was detected 
using the Millipore Immunoperoxidase Secondary Detection 
System (EMD Millipore Corporation). After brightfield 
imaging, images were converted to grayscale, and the area of 
the defect was outlined using ImageJ (National Institutes of 
Health). The images were thresholded to match the positive 
staining in the original image. The percent positive staining 
was computed as the number of black (positive) pixels 
divided by the total number of pixels in the defect.
Statistical analyses were performed using SPSS (version 
21, IBM). Normality of each dataset was verified using the 
Kolmogorov-Smirnoff test. Given that all data for the exper-
imental groups was normally distributed, a 2-way analysis 
of variance was used for most outcome measures, using 
treatment with TGF-β3 or MSCs as independent factors. For 
μCT analysis, the zone within the subchondral bone was an 
additional independent factor. After performing the analysis 
of variance, Bonferroni or Games-Howell post hoc tests 
were performed, depending on whether or not the variances 
were equal between groups. Significance was set at P < 0.05. 
All experimental groups were also compared with the nor-
mal control via either t tests or Mann-Whitney U tests, 
depending on the normality of the control data. To control 
for type I error, a Bonferroni correction was used, and sig-
nificance was set at P < 0.013 for these comparisons.
Results
At the time of surgery, a small amount of bleeding occurred 
during defect creation. Bleeding was minimized prior to 
hydrogel implantation, and all hydrogels readily gelled in 
the defects within 10 minutes and maintained complete 
defect fill prior to closure. All animals were mobile/stand-
ing on the day of or the day following surgery. No animals 
had noticeable gait deficits after 1 week.
Two weeks after surgery, defects within one animal were 
examined to assess the patency of the hydrogel within the 
defect as well as the presence of delivered MSCs. Confocal 
imaging revealed the presence of both implanted MSCs and 
endogenous cells at the central defect surface for the HA/
MSCs and HA/MSCs/TGF groups (Fig. 2A). At the defect 
edge, the implanted MSCs remained within the hydrogel and 
were not present in the adjacent cartilage. Endogenous cells 
were also present within the defect for the HA and HA/TGF 
groups (Fig. 2A). Histological staining of the cells and matrix 
via hematoxylin and eosin showed the presence of the hydro-
gel within the defect site for all groups (Fig. 2B). Partial 
incorporation of the construct was observed, and a hypercel-
lular, fibrous matrix surrounded the hydrogel within the 
defect site for all groups.
Six weeks after surgery, a white/red fibrous tissue was 
present within the defects with incomplete filling (Fig. 3A). 
Little to no damage was found in the adjacent cartilage, and 
no marked differences were noted between experimental 
groups. From μCT measurements, mean values for defect 
fill ranged from 70% for the HA/MSCs/TGF group to 87% 
for the HA group (Fig. 3B). No statistically significant 
effect was observed with the inclusion of TGF-β3 (P > 
0.05). Interestingly, groups containing MSCs had defect fill 
values 12% to 18% lower than defects without MSCs (P < 
0.05). The interaction term between treatment with TGF-β3 
and MSCs was not statistically significant (P > 0.05).
Histological evaluation of proteoglycans and fibrous tissue 
deposition at the repair site was assessed via Safranin O/Fast 
Green staining (Fig. 4). Most specimens had at least some 
positive staining for proteoglycans, although the amount of 
Figure 2. Short-term integration of hyaluronic acid hydrogels 
and persistence of delivered stem cells. (A) Confocal images 
of defect site after 2 weeks in vivo following treatment with 
hyaluronic acid hydrogels only or with mesenchymal stem 
cells (scale bar = 500 µm; HA = hyaluronic acid; MSCs = 
mesenchymal stem cells). All cell nuclei labeled blue. Implanted 
cells also marked with cell tracker (red). Host cell nuclei show 
as blue. (B) Hematoxylin and eosin staining of cell nuclei and 
matrix showing incorporation of the HA hydrogels for all groups 
at 2 weeks postimplantation (*HA hydrogel, **adjacent cartilage, 
***underlying bone, scale bar = 500 µm; TGF = microspheres 
containing transforming growth factor–β3).
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staining was highly variable between the best and worst 
samples. The best samples featured robust staining for pro-
teoglycans, while the worst samples were filled with almost 
entirely fibrous tissue. Semiquantitative ICRS-II scoring 
(Fig. 4) of matrix staining revealed similar mean values 
ranging from 21 for the HA group to 34 for the HA/MSC/
TGF group. No effect was observed due to treatment with 
either TGF-β3 or MSCs (P > 0.05). However, all experi-
mental groups had lower matrix staining scores compared 
with normal controls (P < 0.05).
Via hematoxylin and eosin staining (Fig. 5), the hydro-
gel was not readily observed at the 6-week time point. In all 
experimental groups, cell morphology ranged from rounded 
cells to more elongated ones, which generally corresponded 
to regions of proteoglycan staining and fibrous tissue 
formation, respectively (Fig. 4). Semiquantification of cell 
morphology revealed similar trends as for matrix staining. 
Scores for the experimental groups were similar, with 
median values ranging from 17 to 35. Again, no effect was 
observed due to treatment with either TGF-β3 or MSCs (P 
> 0.05), and all treatment groups had scores 59% to 72% 
lower than normal controls (P < 0.05). Other scoring cate-
gories, such as cell clustering at the surface, surface archi-
tecture, basal integration, vascularization, and tidemark 
formation, revealed similar trends (Suppl. Fig. S1).
Deposition of type II collagen was assessed via immuno-
histochemistry (Fig. 6). All groups showed some level of 
positive staining, although the amount of staining had con-
siderable variability between the best and worst specimens. 
Quantification of type II collagen staining showed that 
treatment with TGF-β3 led to increased staining intensity 
for the HA/TGF and HA/MSCs/TGF groups (53% ± 29% 
and 50% ± 22%, respectively) relative to the HA and HA/
MSCs groups (32% ± 17% and 29% ± 18%, respectively, 
P < 0.05). The presence of MSCs had little effect, as com-
parisons between the HA and HA/MSCs groups and 
between the HA/TGF and HA/MSCs/TGF groups were not 
statistically significant (P > 0.05). The interaction term 
between treatment with TGF-β3 and MSCs was also not 
statistically significant (P > 0.05). All groups had signifi-
cantly lower positive staining compared with the normal 
tissue (96% ± 3%, P < 0.05).
Finally, the amount of subchondral bone remodeling 
underneath the defects was quantified via μCT and histo-
logical scoring (Fig. 7). No effect was observed due to treat-
ment with either TGF-β3 or MSCs (P > 0.05), but a 
significant effect was found for zone of analysis (P < 0.05). 
The interaction term between these variables was not statis-
tically significant (P > 0.05). All experimental groups had 
lower BV/TV values near the original cartilage/bone inter-
face (within 2 mm) relative to a region further from the 
original cartilage/bone interface (3-5 mm) (P < 0.05). Near 
the interface, these groups were also 48% to 68% lower 
than normal (P < 0.05), while no differences were found 
relative to normal controls in the region further removed 
from the interface (P > 0.05). Histological scoring for bone 
remodeling, which considers the entirety of the bone remod-
eling response, revealed a wide range of scores for the 
experimental groups. No statistically significant differences 
were found due to treatment with TGF-β3 or MSCs (P > 
0.05), and scores for the experimental groups ranged from 
36% to 71% lower than normal controls (P < 0.05).
Discussion
In this study, we evaluated the individual and synergistic 
effects of growth factor (TGF-β3) and cell (MSCs) delivery 
within an HA hydrogel on cartilage repair and subchondral 
bony remodeling in a porcine model of full thickness carti-
lage repair. Most interestingly, TGF-β3 led to a marked 
increase in positive staining for collagen type II within the 
defects, while delivery of MSCs did not. Neither TGF-β3 
Figure 3. (A) Gross images of cartilage defects after 6 weeks 
of healing (scale bar = 2 mm; HA = hyaluronic acid; MSCs 
= mesenchymal stem cells; TGF = microspheres containing 
transforming growth factor-β3). (B) Quantification of defect fill 
via micro-computed tomography reconstruction (+P < 0.05 vs. 
non-MSC groups).
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nor MSCs had an impact on other histological semiquanti-
tative scoring, and in fact, delivery of MSCs led to signifi-
cantly less defect fill as assessed by μCT. For all these 
outcome measurements, no synergy was found between 
TGF-β3 and MSC treatment when delivered together, con-
trary to our hypothesis that the combined treatment with 
MSCs and TGF-β3 in the HA hydrogels would result in the 
most robust positive healing response.
By 6 weeks, TGF-β3 elicited a significant improvement 
in the formation of type II collagen, but had little impact on 
defect fill or histological measures, including proteoglycan 
staining. Many studies have examined the use of TGF-β3 
for cartilage repair in vivo,22-27 but direct comparisons are 
difficult due to differences in the delivery mechanism of the 
growth factor, the dose, or the isoform used. In our group, a 
recent study in mini-pigs showed that delivery of TGF-β3 
from fibrous HA scaffolds with a similar release profile 
combined with microfracture also increased collagen type 
II content by 12 weeks.22 In addition, delivery of TGF-β3 
improved overall semiquantitative histological scoring of 
the repair tissue in those defects. From the current study, it 
is unclear whether later time points would reveal similar 
improvements in histological measurements due to TGF-β3 
treatment. The dose and timing of TGF-β3 delivery used in 
this study was based on in vitro results by our group show-
ing that delivery of 50 to 100 ng/mL of TGF-β3 over a 
1-week period was sufficient to induce and maintain chon-
drogenesis of MSCs52 over 12 weeks, with this transient 
Figure 4. Histological staining (Safranin O/fast green) for proteoglycans (red) and collagens (green) of full thickness cartilage defects 
treated with hyaluronic acid (HA) hydrogels, microspheres containing transforming growth factor–β (TGF), and mesenchymal stem 
cells (MSCs) showing entire defect and adjacent normal tissue. Numbers represent overall histological score for that specimen  
(*P < 0.05 vs. normal; scale bar = 2 mm).
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Figure 6. Immunostaining for collagen type II showing entire defect following treatment with hyaluronic acid (HA) hydrogels, 
microspheres containing transforming growth factor–β (TGF), and mesenchymal stem cells (MSCs) (*P < 0.05 vs. normal, ^P < 0.05 vs. 
non-TGF groups; scale bar = 2 mm).
Figure 5. Histological staining (hematoxylin and eosin) for cells and matrix of full thickness cartilage defects treated with hyaluronic 
acid (HA) hydrogels, microspheres containing transforming growth factor–β (TGF), and mesenchymal stem cells (MSCs) showing 
entire defect and adjacent normal tissue (*P < 0.05 vs. normal; scale bar = 2 mm).
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high-dose delivery resulting in superior outcomes com-
pared to lower doses delivered over the same 12 week time 
period. The alginate microspheres used in this study have 
been shown to mediate controlled release of TGF-β3 for up 
to one week in vitro.45 We did not directly assess the impact 
of the in vivo growth factor release profile, but there is some 
evidence in the pig model that controlled release of growth 
factors provides better long-term repair tissue at 12 months 
relative to a bolus delivery.23-25 Additional controlled stud-
ies are warranted. The isoform of TGF could also explain 
differences between studies; however, Ng et al.13 have 
shown similar results in a direct comparison between TGF-
β3 and TGF-β1 on in vitro chondrogenesis.
Our study showed little positive impact of allogeneic 
MSCs on the repair response despite their presence in sig-
nificant numbers in the repair tissue, confirmed using cell 
labeling. In fact, we found significantly less defect fill, and 
although not statistically significant, the groups containing 
MSCs had the poorest median scores in terms of subchon-
dral bone remodeling. There are a host of studies in the lit-
erature on the effects of MSCs on cartilage healing, with 
some showing positive effects and others showing little 
impact, or even a negative one.28-38 Again, a variety of dif-
ferences exist between studies making comparisons diffi-
cult, including species and age of the animals, delivery 
method (injection vs. within a scaffold), the source of the 
MSCs within the body, the in vitro preculture methods used, 
and the use of autologous cells, allogeneic cells, or xenoge-
neic cells. In our study, we isolated MSCs from the bone 
marrow of a donor pig of similar age, expanded in serum 
containing media, and implanted those cells within an HA 
hydrogel into a different animal. It is unclear whether or not 
autologous cells would achieve better results in this model, 
and future studies on this topic are warranted.
Other large animal studies have precultured MSCs in 
vitro within a chemically defined media known to induce 
chondrogenesis prior to implantation.28-34 In the ovine model, 
Marquass et al.34 showed that such preculture of MSCs could 
result in better in vivo outcomes relative to non-precultured 
MSCs or articular chondrocytes. However, Chang et al.33 
found dissimilar findings in the pig model, with undifferenti-
ated MSCs providing superior repair versus MSCs precul-
tured in the presence of TGF-β3. Further complicating the 
issue, Miot et al.28 found that 2 weeks of preculture within a 
scaffold material was best for articular chondrocytes in terms 
of potential for in vivo repair in the goat model, relative to 
both shorter (2 days) and longer (6 weeks) periods of precul-
ture. Our recent work using HA hydrogels is consistent with 
this finding in that the best results in an in vitro “integration” 
assay were found for an intermediate culture period.20 These 
findings were dependent on the maturation trajectory of the 
construct properties with time, not the maturation state at the 
time of “implantation.” However, additional studies are still 
needed to confirm this hypothesis in vivo,20 and the mecha-
nism by which in vitro preculture might enhance in vivo 
results has not yet been elucidated. One potential mechanism 
is that a construct with specific mechanical function and 
extracellular matrix content may allow more appropriate load 
transfer to the cells, which in turn, may elicit even more 
matrix production and more appropriate mechanical func-
tion. In addition, culture within highly controlled in vitro con-
ditions can ensure consistent chondrogenesis of the MSCs 
prior to implantation. At the right dosage, such short-term 
delivery of chondrogenic factors might allow the MSCs to 
maintain a chondrogenic phenotype even under less ideal 
conditions within the joint.
This study focused on the effects of MSCs and TGF-β 
delivered within hydrogels on cartilage repair, and was not 
Figure 7. Effects of treatment on subchondral bone remodeling. (A) Quantification of bone volume per total volume via micro-
computed tomography at regions 0 to 2 mm and 3 to 5 mm under the original injury site (*P < 0.05 vs. normal, +P < 0.05 vs. 0- to 
2-mm zone for same group). (B) Histological scoring of bone remodeling via the ICRS-II scoring system (*p<0.05 vs. normal).
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designed to compare the potential contributions of the sub-
chondral bone and synovium on the repair response. 
However, it is likely that both may play a role. In the current 
and previous work, we have noted a “covering” over the 
implanted hydrogels that forms at the articular surface and 
likely involves some cells from the synovium.21 At the same 
time, upon creation of the defects, a small amount of bleed-
ing occurred from the subchondral bone, and remodeling of 
the bone was noted as in our previous studies,21 which also 
likely plays a role in the development of the repair tissue.
The combination of MSCs and TGF did not produce 
positive synergistic results for any of the outcome measures 
in this study, similar to some other studies.43,44 Yet, others 
have found the addition of TGF delivery with MSCs 
enhanced results relative to MSCs alone.41,42 Many of these 
studies lack full factorial designs, however, preventing the 
determination of individual and synergistic effects of the 
TGF and MSCs. Even in the small number of studies with 
full factorial designs, the results are unclear. For example, 
Mrugala et al.40 used a partial-thickness defect model in 
sheep and found that the addition of MSCs with TGF-β3 
within a chitosan powder vehicle appeared to have a small 
additional benefit relative to the application of TGF-β3 and 
chitosan alone. However, Im and Lee39 reported that com-
bined delivery of adipose derived stem cells with TGF-β2 
and BMP-7 for the treatment osteochondral defects in rab-
bits did not improve the histological appearance of the 
repair relative to growth factor treatment alone. Neither 
study revealed a positive effect due to the cells alone. As 
above, comparisons between studies are difficult due to a 
variety of experimental differences.
One interesting finding in this work was the fact that the 
HA hydrogel degraded rapidly in vivo, with partial incorpo-
ration at 2 weeks and complete incorporation by 6 weeks. 
Importantly, little apparent inflammation response was 
observed due to the degradation of the HA at either time 
point. In our previous in vivo studies using the mini-pig 
model,21,22 no impact was observed for HA scaffolds alone 
relative to untreated control defects for any of the outcome 
measures presented here. This was true for both HA hydro-
gels and electrospun HA fibers. As such, no untreated con-
trol group was included in this study.
Collectively, these data suggest that in the early-term 
healing response, TGF-β3 can have a positive impact on the 
formation of collagen type II within the defect, while allo-
geneic MSCs added little benefit toward the promotion of 
the healing response. Combination of TGF-β3 and MSCs 
has no synergistic effect in this model. Studies are war-
ranted to determine whether combination of these factors 
can provide a superior repair long-term. Furthermore, the 
role of age in the repair response should be further explored, 
given the decrement in endogenous progenitor cells with 
aging. In conclusion, these data suggest that combination of 
MSCs with growth factors and scaffold materials followed by 
a period of preculture using a traditional in vitro tissue engi-
neering approach may provide a better outcome compared 
with direct implantation of cells and chondrogenic factors.
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